Loves by Domus1h
The great Nan Goldin exhibition now in Berlin
This Will Not End Well” is the incredible retrospective that the Neue Nationalgalerie dedicates to one of the most important ...
Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
Vehicle crash causes delays near Tidewater Drive
A vehicle crash caused delays on I-64 near Tidewater Drive Tuesday morning. According to the Virginia Department of ...
TipRanks on MSN3h
Moderna initiated with a Hold at Berenberg
Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says ...
S&P 500 Gains and Losses Today: Uber Falls as Trump Eyes Looser Self-Driving Rules
The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated earnings report ...
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential
Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.
Cramer's Mad Dash: Moderna gets upgrade from HSBC
CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...
Moderna upgraded to Hold from Reduce at HSBC
HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...